MedTrace Logo

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT07133750 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-21

No results posted yet for this study

Summary

PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.

Conditions

  • CRC (Colorectal Cancer)

Interventions

DRUG

PM8002

IV infusion

DRUG

Chemotherapy Regimen 1

IV infusion

DRUG

Chemotherapy Regimen 2

Oral administration and IV infusion

Sponsors & Collaborators

  • BioNTech SE

    collaborator INDUSTRY

  • Biotheus Inc.

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu, PhD, MD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2026-08-31
Completion
2029-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07133750 on ClinicalTrials.gov